Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab govitecan + bevacizumab for NSCLC brain metastases
2024-514066-40-00Phase 2Authorised
- Sponsor
- Maastricht University Medical Center+
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan and bevacizumab in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by Maastricht University Medical Center+. Primary endpoint: Brain metastasis objective response rate (RANO-BM). Planned start Jan 2025; status: authorised.
02
Drugs
sacituzumab govitecanbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on 2024-514066-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514066-40-00.